This story has been updated from a previous version.
NEW YORK, Feb 22 - EraGen Biosciences of Alachua, Fla., said Thursday its CEO and president, Gideon Shapiro, stepped down in order to pursue other activities.
Shapiro said it was “a mutual decision for a new direction the company will be pursuing that needs new expertise.”
He declined to comment any further on EraGen’s new direction, but noted, “bioinformatics is still a core technology for the company.”
“The market is clearly demanding more product-oriented companies,” Shapiro added. “It’s a question of building out the product line and defining what is the value of that product line given our core nucleic acid and bioinformatics technologies.”
Shapiro said he would continue with the company to assist with its business development and financing. “It’s not a hostile situation,” he said.
Shapiro will also remain a member of EraGen’s board of directors “for the foreseeable future.”
“The Board wishes to thank Dr. Shapiro for his guidance and direction of EraGen over the past 18 months,” Stan Yakatan, member of EraGen’s board of directors, said in a statement.
EraGen did not say who would replace Shapiro.
EraGen, a developer of clinical diagnostic and bioinformatics technologies, also said that it appointed Gary Alianell as chief operating officer .
Alianell’s main task will be to commercialize EraGen’s clinical diagnostic and genotyping products. He will also be in charge of overseeing the company's business strategies and bioinformatics product development efforts.
Alianell previously worked at Oxford GlycoSystems, Transgenomic, and NucleoTech Corporation, where he was CEO and president.